Compare Gemini Space Station Inc (GEMI) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gemini Space Station Inc vs Recursion Pharmaceuticals Inc — how do they compare? Gemini Space Station Inc trades at $4.43 (market cap $579.55M), while Recursion Pharmaceuticals Inc trades at $4.33 (market cap $2.14B). The key difference: Recursion Pharmaceuticals Inc is far larger — about 3.7× Gemini Space Station Inc's market cap, and Recursion Pharmaceuticals Inc is trading nearer its 52-week high, Gemini Space Station Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Gemini Space Station Inc for 14 Days and Recursion Pharmaceuticals Inc for 23 Days on average.
| GEMI | RXRX | |
|---|---|---|
Market Cap | $579.55M | $2.14B |
Volume | 1,882,406 | 30,789,535 |
Sector | Financials | Health |
52-Week High | $25.41 | $6.79 |
52-Week Low | $3.54 | $2.84 |
Typical Hold Time | 14 Days | 23 Days |
Enterprise Value | $558.57M | $1.66B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gemini Space Station (GEMI) trades at $4.40, down 2% today amid bearish technical signals and persistent financial losses. The company reported Q2 2026 revenue growth of 37% year-over-year but missed earnings expectations with a net loss of -$0.89 per share. Despite expanding services revenue and new product offerings, negative profit margins and cash flow challenges persist. Technical indicators show oversold conditions with RSI readings below 11, while moving averages signal continued downward pressure.
The stock faces significant fundamental headwinds with negative margins and cash burn, though analyst consensus suggests 19% upside to the $5.25 price target. Key risks include ongoing litigation, competitive pressures in financial services, and the company's ability to achieve profitability. Recent SEC approval for tokenized stock trading could provide growth opportunities if execution improves.
RXRX trades at $4.255, down 0.35% on the day, with a bullish technical signal from moving averages. The company reported a net loss of $644.76 million in 2025 on $74.26 million revenue, with a negative net income margin of -961.97%. Recent news highlights strategic AI partnerships, including an extended data license with Tempus AI announced September 21, 2026, and pipeline progress presented at the Morgan Stanley Healthcare Conference.
The outlook remains speculative, driven by AI-powered drug discovery potential and partnership milestones, but significant execution risk persists due to heavy losses and high cash burn. Analyst consensus is mixed with 40% buy ratings, reflecting optimism for long-term platform value against near-term financial challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Gemini Space Station Inc
Gemini Space Station Inc is the parent company of the Gemini crypto ecosystem, founded by Cameron and Tyler Winklevoss. It operates as a regulated digital asset exchange and custodian, providing a platform for individuals and institutions to trade, store, and stake cryptocurrencies while serving as a trusted bridge between legacy finance and the decentralized web.
Read more on GEMI →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
